Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer

Lung Cancer

Volumn 41, Issue 2, 2003, Pages 215-219

  Braybrooke, J P ^a   Ranson, M ^b   Manegold, C ^c   Mattson, K ^d   Thatcher, N ^b   Cheverton, P ^e   Sekiguchi, M ^f   Suzuki, M ^f   Oyama, R ^e   Talbot, D C ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c Thoraxklinik   (Germany)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Daiichi Pharmaceuticals UK Ltd   (United Kingdom)

^f DAIICHI SANKYO CO   (Japan)

Author keywords

DX 8951f; Exatecan; Non small cell lung cancer; Phase II; Topoisomerase I

Indexed keywords

DX 8951 F; EXATECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIARRHEA; DRUG ACTIVITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SCREENING; DYSPNEA; FATIGUE; FEMALE; HISTOLOGY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THORAX PAIN; THROMBOCYTOPENIA; TOXICITY; TUMOR GROWTH; VOMITING;

EID: 0037491620     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00190-9     Document Type: Article

References (20)

1. Rapp E., Pater J.L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J. Clin. Oncol. 6:1988;633-641.
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311:1995;899-909.
3. Ranson M., Davidson N., Nicolson M., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 92:2000;1074-1080.
4. Mitsui I., Kumazawa E., Hirota Y., et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn. J. Cancer Res. 86:1995;776-782.
5. Rowinsky E.K., Johnson T.R., Geyer C.E., et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J. Clin. Oncol. 18:2000;3151-3163.
6. Boige V., Raymond E., Faivre S., et al. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-min infusion every 3 weeks in patients with advanced cancer. J. Clin. Oncol. 18:2000;3986-3992.
7. Royce M.E., Hoff P.M., Dumas P., et al. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J. Clin. Oncol. 19:2001;1493-1500.
8. Braybrooke JP, Boven E, Bates NP, et al. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f) using a weekly 30-min intra-venous infusion, in patients with advanced solid malignancies, Ann Oncol 2003, in press.
9. National Cancer Institute guidelines for the reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
10. Green S., Weiss G. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs. 10:1992;239-253.
11. Oguma T., Ohshima Y., Nakaoka M. Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection. J. Chromatogr. B Biomed. Sci. Appl. 740:2000;237-245.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials. 10:1989;1-10.
13. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 346:2002;92-98.
14. Anderson H., Lund B., Bach F., Thatcher N., et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1821-1826.
15. Vokes E.E., Rosenberg R.K., Jahanzeb M., et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non- small-cell lung cancer. J. Clin. Oncol. 13:1995;637-644.
16. Perez-Soler R., Fossella F.V., Glisson B.S., et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol. 14:1996;503-513.
17. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91:1999;66-72.
18. White S., Cheeseman S., Thatcher N., et al. Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin. Cancer Res. 6:2000;868-873.
19. Kano Y., Suzuki K., Akutsu M., et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer. 50:1992;604-610.
20. Kudoh S., Takada M., Masuda N., et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn. J. Cancer Res. 84:1993;203-207.